Nuvectis Pharma (NVCT) Operating Expenses (2021 - 2026)
Nuvectis Pharma (NVCT) posted Operating Expenses of $6.3 million for Q1 2026, down 17.82% sequentially from $7.6 million in Q4 2025, and up 12.43% YoY from $5.6 million in Q1 2025.
Nuvectis Pharma (NVCT) Operating Expenses (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Operating Expenses for 6 years, with the latest figure at $6.3 million in Q1 2026.
- Quarterly Operating Expenses rose 12.43% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.3 million (up 34.48% YoY) and the FY2025 annual result came in at $28.0 million, up 38.74% from the prior year.
- Operating Expenses fell to $6.3 million in Q1 2026 per NVCT's latest filing, from $7.6 million in the prior quarter.
- Over five years, Operating Expenses peaked at $7.8 million in Q3 2025 and troughed at $2.0 million in Q1 2022.
- A 5-year average of $5.6 million and a median of $5.9 million in 2022 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 199.25% in 2022, down 39.83% in 2022.
- Over 5 years, Operating Expenses stood at $6.8 million in 2022, then climbed by 1.3% to $6.9 million in 2023, then dropped by 6.07% to $6.4 million in 2024, then climbed by 18.11% to $7.6 million in 2025, then slipped by 17.82% to $6.3 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $6.3 million, $7.6 million, and $7.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | 7.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.20 Mn |
| Mar 31, 2026 | 6.26 Mn |
| Dec 31, 2025 | 7.62 Mn |
| Sep 30, 2025 | 7.79 Mn |
| Jun 30, 2025 | 6.60 Mn |
| Mar 31, 2025 | 5.57 Mn |
| Dec 31, 2024 | 6.45 Mn |
| Sep 30, 2024 | 4.36 Mn |
| Jun 30, 2024 | 4.64 Mn |
| Mar 31, 2024 | 4.40 Mn |
| Dec 31, 2023 | 6.87 Mn |
| Sep 30, 2023 | 6.16 Mn |
| Jun 30, 2023 | 5.77 Mn |
| Mar 31, 2023 | 4.10 Mn |
| Dec 31, 2022 | 6.78 Mn |
| Sep 30, 2022 | 5.94 Mn |
| Jun 30, 2022 | 3.57 Mn |
| Mar 31, 2022 | 2.01 Mn |
| Dec 31, 2021 | 2.27 Mn |
| Sep 30, 2021 | 4.67 Mn |